Primary Prevention of Glucocorticoid-Induced Osteoporosis with Intravenous Pamidronate and Calcium: A Prospective Controlled 1-Year Study Comparing a Single Infusion, an Infusion Given Once Every 3 Months, and Calcium Alone

Oxford University Press (OUP) - Tập 16 Số 1 - Trang 104-112 - 2001
Yves Boutsen1, Jacques Jamart2, W. Esselinckx1, J.-P. Devogelaer3
1Department of Rheumatology, Université Catholique de Louvain, University Hospital in Mont‐Godinne, Yvoir, Belgium
2Department of Biostatistics, Université Catholique de Louvain, University Hospital in Mont‐Godinne, Yvoir, Belgium
3Department of Rheumatology, Université Catholique de Louvain, St. Luc University Hospital, Brussels, Belgium

Tóm tắt

Abstract The aim of this study was to compare the action of two regimens of intravenous (iv) pamidronate in the primary prevention of glucocorticoid-induced osteoporosis (GC-OP). The primary purpose of the study was to determine whether any differences in bone mineral density (BMD) appeared after 1 year. A secondary endpoint aimed at assessing the remodeling parameters in order to better understand the mechanisms of action of the various regimens. Thirty-two patients, who required first-time, long-term glucocorticoid therapy at a daily dose of at least 10 mg of prednisolone, were studied. Simultaneously with the initiation of their glucocorticoid treatment, patients also were randomly allocated to receive a single iv infusion of 90 mg of pamidronate at the start (group A); a first infusion of 90 mg of pamidronate followed, subsequently, by an iv infusion of 30 mg pamidronate every 3 months (group B); and a daily 800-mg elemental calcium supplement given as calcium carbonate (group C), which also was taken by patients in groups A and B. Patients were matched for starting glucocorticoid doses, sex, menopausal status, and hormonal replacement therapy. Lumbar spine and hip (total and subregions) BMDs were measured at the outset and repeated at 6-month intervals by dual-energy X-ray absorptiometry (DXA; Hologic QDR-2000). Bone turnover was assessed by measurement of total and bone-specific serum alkaline phosphatase activity (B-ALP), serum osteocalcin (OC), and serum C-telopeptide cross-links of type I collagen (CTX). After 1 year, the mean BMD changes for groups A, B, and C were, respectively, 1.7, 2.3, and −4.6% at the lumbar spine; 1.2, 1.2, and −3.1% at the femoral neck; 1.0, 2.6, and −2.2% for the total hip region. No difference was observed between pamidronate regimens but a highly significant difference was observed between both pamidronate regimens and the control group at the lumbar spine (p < 0.001), at the femoral neck (p < 0.01), and for the total hip (p < 0.05). A significant decrease of serum C-telopeptide was observed, after 3 months, in groups A and B (p = 0.029), but a sustained decrease of bone resorption over time was observed only in group B. As far as BMD evolution over 1 year was concerned, iv pamidronate, given either as a single infusion or once every 3 months, effectively achieved primary prevention of GC-OP.

Từ khóa


Tài liệu tham khảo

Reid, 1998, Glucocorticoid-induced osteoporosis: Assessment and treatment, J Clin Densitometry, 1, 65, 10.1385/JCD:1:1:65

Eastell, 1998, A UK Consensus Group on management of glucocorticoid-induced osteoporosis: An update, J Intern Med, 244, 271, 10.1046/j.1365-2796.1998.00408.x

Lane, 1998, The science and therapy of glucocorticoid-induced bone loss, Endocrinol Metab Clin North Am, 27, 465, 10.1016/S0889-8529(05)70017-7

Ishida, 1998, Glucocorticoid-induced osteoporosis: Both in vivo and in vitro concentrations of glucocorticoids higher than physiological levels attenuate osteoblast differentiation, J Bone Miner Res, 13, 1822, 10.1359/jbmr.1998.13.12.1822

Weinstein, 2000, Apoptosis and osteoporosis, Am J Med, 108, 153, 10.1016/S0002-9343(99)00420-9

Adinoff, 1983, Steroid-induced fractures and bone loss in patients with asthma, N Engl J Med, 309, 265, 10.1056/NEJM198308043090502

Cooper, 1988, Physical activity, muscle strength, and calcium intake in fracture of the proximal femur in Britain, BMJ, 297, 1443, 10.1136/bmj.297.6661.1443

Baltzan, 1999, Hip fractures attributable to corticosteroid use, Lancet, 353, 1327, 10.1016/S0140-6736(98)04835-1

LoCascio, 1990, Bone loss in response to long-term glucocorticoid therapy, Bone Miner, 8, 39, 10.1016/0169-6009(91)90139-Q

Julian, 1991, Rapid loss of vertebral mineral density after renal transplantation, N Engl J Med, 325, 544, 10.1056/NEJM199108223250804

Laan, 1993, Low-dose prednisone induces rapid reversible axial bone loss in patients with rheumatoid arthritis, Ann Intern Med, 119, 963, 10.7326/0003-4819-119-10-199311150-00001

Reid, 1988, Prevention of steroid-induced osteoporosis with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD), Lancet, 1, 143, 10.1016/S0140-6736(88)92721-3

Reid, 1988, Two-year follow-up of bisphosphonate (APD) treatment in steroid osteoporosis, Lancet, 2, 1144, 10.1016/S0140-6736(88)90566-1

Gallacher, 1992, Intravenous pamidronate in the treatment of osteoporosis associated with corticosteroid dependent lung disease: An open pilot study, Thorax, 47, 932, 10.1136/thx.47.11.932

Worth, 1994, Therapy of steroid-induced bone loss in adult asthmatics with calcium, vitamin D, and a diphosphonate, Am J Respir Crit Care Med, 150, 394, 10.1164/ajrccm.150.2.8049820

Adachi, 1994, Intermittent cyclic therapy with etidronate in the prevention of corticosteroid induced bone loss, J Rheumatol, 21, 1922

Skingle, 1994, Increased bone density in patients on steroids with etidronate, Lancet, 344, 543, 10.1016/S0140-6736(94)91932-1

Mulder, 1994, Intermittent cyclical etidronate in the prevention of corticosteroid-induced bone loss, Br J Rheum, 33, 348, 10.1093/rheumatology/33.4.348

Diamond, 1995, Cyclical etidronate plus ergocalciferol prevents glucocorticoid-induced bone loss in postmenopausal women, Am J Med, 98, 459, 10.1016/S0002-9343(99)80345-3

Struys, 1995, Cyclical etidronate reverses bone loss of the spine and proximal femur in patients with established corticosteroid-induced osteoporosis, Am J Med, 99, 235, 10.1016/S0002-9343(99)80154-5

Falcini, 1996, Intravenous administration of alendronate counteracts the in vivo effects of glucocorticoids on bone remodeling, Calcif Tissue Int, 58, 166

Eastell, 1996, Osteoporosis, 391

Adachi, 1997, Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis, N Engl J Med, 337, 382, 10.1056/NEJM199708073370603

Boutsen, 1997, Primary prevention of glucocorticoid-induced osteoporosis with intermittent intravenous pamidronate: A randomized trial, Calcif Tissue Int, 61, 266, 10.1007/s002239900334

Roux, 1998, Randomized trial of effect of cyclical etidronate in the prevention of corticosteroid-induced bone loss, J Clin Endocrinol Metab, 83, 1128, 10.1210/jcem.83.4.4742

Saag, 1998, Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis, N Engl J Med, 339, 292, 10.1056/NEJM199807303390502

Saag, 1998, Effects of alendronate for two years on BMD and fractures in patients receiving glucocorticoids, Bone, 23, S182

Reeves, 1998, Intravenous bisphosphonate prevents symptomatic osteoporotic vertebral collapse in patients after liver transplantation, Liver Transpl Surg, 4, 404, 10.1002/lt.500040508

Sebalt, 1999, 36 month intermittent cyclical etidronate treatment in patients with established corticosteroid induced osteoporosis, J Rheumatol, 26, 1545

Reid, 2000, Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: A randomized trial, J Bone Miner Res, 15, 1006, 10.1359/jbmr.2000.15.6.1006

Amin, 1999, The role of vitamin D in corticosteroid-induced osteoporosis: A meta-analytic approach, Arthritis Rheum, 42, 1740, 10.1002/1529-0131(199908)42:8<1740::AID-ANR25>3.0.CO;2-E

Devogelaer, 1992, Current Research in Osteoporosis and Bone Mineral Measurement, 2

Minne, 1988, A newly developed spine deformity index (SDI) to quantitate vertebral crush fractures in patients with osteoporosis, Bone Miner, 3, 335

Liang, 1986, Longitudinal data analysis using generalized linear models, Biometrika, 73, 13, 10.1093/biomet/73.1.13

Davis, 1993, A computer program for regression analysis of repeated measures using generalized estimating equations, Comput Methods Programs Biomed, 40, 15, 10.1016/0169-2607(93)90046-N

Devogelaer, 1981, L'atteinte hépatique dans la pseudo-polyarthrite rhizomélique, Rhumatologie, 33, 131

Hall, 1995, Markers of bone metabolism in postmenopausal women with rheumatoid arthritis, Arthritis Rheum, 38, 902, 10.1002/art.1780380705

Nielsen, 1988, The effect of single oral doses of prednisone on the circadian rhythm of serum osteocalcin in normal subjects, J Clin Endocrinol Metab, 67, 1025, 10.1210/jcem-67-5-1025

Kotowicz, 1990, Relationship of glucocorticoid dosage to serum bone GLA-protein concentration in patients with rheumatologic disorders, Arthritis Rheum, 33, 1487, 10.1002/art.1780331005

Gram, 1998, Effects of short-term treatment with prednisolone and calcitriol on bone and mineral metabolism in normal men, Bone, 23, 297, 10.1016/S8756-3282(98)00097-0

Thiebaud, 1997, Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis, Am J Med, 103, 298, 10.1016/S0002-9343(97)00249-0

Christgau, 1998, Clinical evaluation of the Serum CrossLaps One Step ELISA, a new assay measuring the serum concentration of bone-derived degradation products of type I collagen C-telopeptides, Clin Chem, 44, 2290, 10.1093/clinchem/44.11.2290

Ravn, 1999, Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women, Bone, 24, 237, 10.1016/S8756-3282(98)00183-5

Fitton, 1991, Pamidronate: A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease, Drugs, 41, 289, 10.2165/00003495-199141020-00009

Adami, 1996, Adverse effects of bisphosphonates, Drug Safety, 14, 158, 10.2165/00002018-199614030-00003

Thiebaud, 1997, An in vitro and in vivo study of cytokines in the acute-phase response associated with bisphosphonates, Calcif Tissue Int, 61, 386, 10.1007/s002239900353

Thông tin
Thông tin xuất bản

Oxford University Press (OUP)

Tập 16 Số 1

104-112

Thông tin tác giả